Teva still owns a minority stake in Alcobra, Globes added and said former Teva vice-president of innovative ventures, Aharon Schwartz, is now Alcobra's chairman.

Alcobra Pharma, an Israel-based drugmaker attention deficit hyperactivity disorder (ADHD) backed by peer Teva’s corporate venturing unit, plans to raise $17.25m in its Nasdaq flotation.

Alcobra would have a market capitalisation of about $100m, according to its regulatory filing.

The company was founded in 2008 by 7 Health Ventures partner Dalia Megiddo and Udi Gilboa, whose investments include Tel Aviv-listed InsuLine Medical, and they are its main shareholders, according to news provider Globes.

Teva still owns a minority stake…